HA
CTKB icon

HHLR Advisors’s Cytek Biosciences CTKB Stock Holding History

HHLR Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5M Hold
6,657,030
– – 3.54% 8
2026
Q1 		$29.1M Hold
6,657,030
– – 1.74% 9
2025
Q4 		$33.6M Hold
6,657,030
– – 1.08% 9
2025
Q3 		$23.1M Hold
6,657,030
– – 0.56% 15
2025
Q2 		$22.6M Hold
6,657,030
– – 0.73% 14
2025
Q1 		$26.7M Hold
6,657,030
– – 0.75% 15
2024
Q4 		$43.2M Hold
6,657,030
– – 1.5% 14
2024
Q3 		$36.9M Hold
6,657,030
– – 0.81% 15
2024
Q2 		$37.1M Hold
6,657,030
– – 0.92% 13
2024
Q1 		$44.7M Hold
6,657,030
– – 0.97% 16
2023
Q4 		$60.7M Hold
6,657,030
– – 1.22% 15
2023
Q3 		$36.7M Hold
6,657,030
– – 0.82% 17
2023
Q2 		$56.9M Sell
6,657,030
-1,046,484
-14% -$9.39M 1.21% 16
2023
Q1 		$70.8M Sell
7,703,514
-981,016
-11% -$10.6M 1.26% 15
2022
Q4 		$88.7M Sell
8,684,530
-72,500
-0.8% -$974K 1.87% 12
2022
Q3 		$129M Hold
8,757,030
– – 3.39% 9
2022
Q2 		$94M Hold
8,757,030
– – 2.01% 13
2022
Q1 		$94.4M Hold
8,757,030
– – 1.97% 12
2021
Q4 		$143M Hold
8,757,030
– – 2.21% 11
2021
Q3 		$187M Buy
+8,757,030
New +$206M 2.45% 11

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

HHLR Advisors's CTKB Position: Q2 2026 in Review

HHLR Advisors held its Cytek Biosciences (CTKB) position steady in Q2 2026 at 6,657,030 shares worth $29.5M. The position accounts for 3.54% of the portfolio, ranked #8.

HHLR Advisors first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $187M in Q3 2021. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • HHLR Advisors held 6,657,030 shares of Cytek Biosciences worth $29.5M as of Q2 2026.
  • HHLR Advisors left its Cytek Biosciences share count unchanged in Q2 2026.
  • Cytek Biosciences made up 3.54% of HHLR Advisors's portfolio in Q2 2026, its #8 holding.
  • HHLR Advisors first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • HHLR Advisors's Cytek Biosciences position peaked at $187M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on HHLR Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.